Does the media prefer OCUL or AQST?

In the previous week, Ocular Therapeutix had 3 more articles in the media than Aquestive Therapeutics. MarketBeat recorded 12 mentions for Ocular Therapeutix and 9 mentions for Aquestive Therapeutics. Aquestive Therapeutics' average media sentiment score of 0.55 beat Ocular Therapeutix's score of 0.35 indicating that Aquestive Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ocular Therapeutix 2 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Aquestive Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer TRVI or AQST?

In the previous week, Aquestive Therapeutics had 3 more articles in the media than Trevi Therapeutics. MarketBeat recorded 9 mentions for Aquestive Therapeutics and 6 mentions for Trevi Therapeutics. Trevi Therapeutics' average media sentiment score of 0.77 beat Aquestive Therapeutics' score of 0.55 indicating that Trevi Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Trevi Therapeutics 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Aquestive Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation and earnings, AQST or HCM?

HUTCHMED has higher revenue and earnings than Aquestive Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Aquestive Therapeutics $44.54M 12.99 -$83.78M -$0.65 N/A HUTCHMED $548.51M 4.35 $456.91M N/A N/A

Is AQST or HCM more profitable?

HUTCHMED has a net margin of 0.00% compared to Aquestive Therapeutics' net margin of -144.63%. Company Net Margins Return on Equity Return on Assets Aquestive Therapeutics -144.63% N/A -52.40% HUTCHMED N/A N/A N/A

Does the media refer more to AQST or HCM?

In the previous week, Aquestive Therapeutics had 7 more articles in the media than HUTCHMED. MarketBeat recorded 9 mentions for Aquestive Therapeutics and 2 mentions for HUTCHMED. HUTCHMED's average media sentiment score of 0.74 beat Aquestive Therapeutics' score of 0.55 indicating that HUTCHMED is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aquestive Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive HUTCHMED 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor AQST or BHC?

In the previous week, Aquestive Therapeutics had 7 more articles in the media than Bausch Health Cos. MarketBeat recorded 9 mentions for Aquestive Therapeutics and 2 mentions for Bausch Health Cos. Bausch Health Cos' average media sentiment score of 1.14 beat Aquestive Therapeutics' score of 0.55 indicating that Bausch Health Cos is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aquestive Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Bausch Health Cos 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Aquestive Therapeutics (AQST) Competitors

$4.61 -0.05 (-1.07%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$4.61 0.00 (-0.11%)

As of 09/18/2026 07:30 PM Eastern

Compare

AQST vs. OCUL, TRVI, HCM, PBH, and BHC

Should you buy Aquestive Therapeutics stock or one of its competitors? Aquestive Therapeutics's main competitors and comparable companies include Ocular Therapeutix (OCUL), Trevi Therapeutics (TRVI), HUTCHMED (HCM), Prestige Consumer Healthcare (PBH), and Bausch Health Cos (BHC). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Aquestive Therapeutics compare to Ocular Therapeutix?

Ocular Therapeutix (NASDAQ:OCUL) and Aquestive Therapeutics (NASDAQ:AQST) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, dividends, earnings, risk, analyst recommendations, valuation, profitability and media sentiment.

In the previous week, Ocular Therapeutix had 3 more articles in the media than Aquestive Therapeutics. MarketBeat recorded 12 mentions for Ocular Therapeutix and 9 mentions for Aquestive Therapeutics. Aquestive Therapeutics' average media sentiment score of 0.55 beat Ocular Therapeutix's score of 0.35 indicating that Aquestive Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ocular Therapeutix	2 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Aquestive Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Aquestive Therapeutics has a net margin of -144.63% compared to Ocular Therapeutix's net margin of -579.10%. Aquestive Therapeutics' return on equity of 0.00% beat Ocular Therapeutix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ocular Therapeutix	-579.10%	-59.89%	-45.99%
Aquestive Therapeutics	-144.63%	N/A	-52.40%

Ocular Therapeutix has a beta of 0.97, suggesting that its stock price is 3% less volatile than the broader market. Comparatively, Aquestive Therapeutics has a beta of 1.48, suggesting that its stock price is 48% more volatile than the broader market.

Ocular Therapeutix presently has a consensus target price of $25.75, suggesting a potential upside of 157.76%. Aquestive Therapeutics has a consensus target price of $9.17, suggesting a potential upside of 98.84%. Given Ocular Therapeutix's higher possible upside, equities research analysts clearly believe Ocular Therapeutix is more favorable than Aquestive Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ocular Therapeutix	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.77
Aquestive Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

59.2% of Ocular Therapeutix shares are owned by institutional investors. Comparatively, 32.5% of Aquestive Therapeutics shares are owned by institutional investors. 3.1% of Ocular Therapeutix shares are owned by insiders. Comparatively, 6.8% of Aquestive Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Aquestive Therapeutics has lower revenue, but higher earnings than Ocular Therapeutix. Aquestive Therapeutics is trading at a lower price-to-earnings ratio than Ocular Therapeutix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ocular Therapeutix	$51.95M	42.23	-$265.94M	-$1.42	N/A
Aquestive Therapeutics	$44.54M	12.99	-$83.78M	-$0.65	N/A

Summary

Aquestive Therapeutics beats Ocular Therapeutix on 9 of the 17 factors compared between the two stocks.

How does Aquestive Therapeutics compare to Trevi Therapeutics?

Trevi Therapeutics (NASDAQ:TRVI) and Aquestive Therapeutics (NASDAQ:AQST) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, earnings, risk, analyst recommendations, profitability, dividends and valuation.

In the previous week, Aquestive Therapeutics had 3 more articles in the media than Trevi Therapeutics. MarketBeat recorded 9 mentions for Aquestive Therapeutics and 6 mentions for Trevi Therapeutics. Trevi Therapeutics' average media sentiment score of 0.77 beat Aquestive Therapeutics' score of 0.55 indicating that Trevi Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Trevi Therapeutics	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Aquestive Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

95.8% of Trevi Therapeutics shares are owned by institutional investors. Comparatively, 32.5% of Aquestive Therapeutics shares are owned by institutional investors. 15.4% of Trevi Therapeutics shares are owned by company insiders. Comparatively, 6.8% of Aquestive Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Trevi Therapeutics has a beta of 1.04, suggesting that its stock price is 4% more volatile than the broader market. Comparatively, Aquestive Therapeutics has a beta of 1.48, suggesting that its stock price is 48% more volatile than the broader market.

Trevi Therapeutics has a net margin of 0.00% compared to Aquestive Therapeutics' net margin of -144.63%. Aquestive Therapeutics' return on equity of 0.00% beat Trevi Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Trevi Therapeutics	N/A	-23.59%	-22.64%
Aquestive Therapeutics	-144.63%	N/A	-52.40%

Trevi Therapeutics has higher earnings, but lower revenue than Aquestive Therapeutics. Trevi Therapeutics is trading at a lower price-to-earnings ratio than Aquestive Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Trevi Therapeutics	N/A	N/A	-$42.76M	-$0.34	N/A
Aquestive Therapeutics	$44.54M	12.99	-$83.78M	-$0.65	N/A

Trevi Therapeutics currently has a consensus price target of $27.08, suggesting a potential upside of 81.16%. Aquestive Therapeutics has a consensus price target of $9.17, suggesting a potential upside of 98.84%. Given Aquestive Therapeutics' higher probable upside, analysts clearly believe Aquestive Therapeutics is more favorable than Trevi Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Trevi Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	3.00
Aquestive Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

Summary

Trevi Therapeutics beats Aquestive Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Aquestive Therapeutics compare to HUTCHMED?

Aquestive Therapeutics (NASDAQ:AQST) and HUTCHMED (NASDAQ:HCM) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their risk, institutional ownership, analyst recommendations, media sentiment, earnings, dividends, valuation and profitability.

32.5% of Aquestive Therapeutics shares are held by institutional investors. Comparatively, 8.8% of HUTCHMED shares are held by institutional investors. 6.8% of Aquestive Therapeutics shares are held by insiders. Comparatively, 3.6% of HUTCHMED shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Aquestive Therapeutics had 7 more articles in the media than HUTCHMED. MarketBeat recorded 9 mentions for Aquestive Therapeutics and 2 mentions for HUTCHMED. HUTCHMED's average media sentiment score of 0.74 beat Aquestive Therapeutics' score of 0.55 indicating that HUTCHMED is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aquestive Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
HUTCHMED	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

HUTCHMED has a net margin of 0.00% compared to Aquestive Therapeutics' net margin of -144.63%.

Company	Net Margins	Return on Equity	Return on Assets
Aquestive Therapeutics	-144.63%	N/A	-52.40%
HUTCHMED	N/A	N/A	N/A

HUTCHMED has higher revenue and earnings than Aquestive Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aquestive Therapeutics	$44.54M	12.99	-$83.78M	-$0.65	N/A
HUTCHMED	$548.51M	4.35	$456.91M	N/A	N/A

Aquestive Therapeutics has a beta of 1.48, meaning that its share price is 48% more volatile than the broader market. Comparatively, HUTCHMED has a beta of 0.24, meaning that its share price is 76% less volatile than the broader market.

Aquestive Therapeutics currently has a consensus target price of $9.17, suggesting a potential upside of 98.84%. HUTCHMED has a consensus target price of $14.87, suggesting a potential upside of 8.75%. Given Aquestive Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Aquestive Therapeutics is more favorable than HUTCHMED.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aquestive Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88
HUTCHMED	2 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.43

Summary

Aquestive Therapeutics beats HUTCHMED on 8 of the 13 factors compared between the two stocks.

How does Aquestive Therapeutics compare to Prestige Consumer Healthcare?

Prestige Consumer Healthcare (NYSE:PBH) and Aquestive Therapeutics (NASDAQ:AQST) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their valuation, institutional ownership, analyst recommendations, dividends, earnings, profitability, risk and media sentiment.

Prestige Consumer Healthcare has a net margin of 15.57% compared to Aquestive Therapeutics' net margin of -144.63%. Prestige Consumer Healthcare's return on equity of 11.39% beat Aquestive Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Prestige Consumer Healthcare	15.57%	11.39%	5.66%
Aquestive Therapeutics	-144.63%	N/A	-52.40%

Prestige Consumer Healthcare currently has a consensus price target of $70.75, suggesting a potential upside of 57.51%. Aquestive Therapeutics has a consensus price target of $9.17, suggesting a potential upside of 98.84%. Given Aquestive Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Aquestive Therapeutics is more favorable than Prestige Consumer Healthcare.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Prestige Consumer Healthcare	1 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.17
Aquestive Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

99.9% of Prestige Consumer Healthcare shares are held by institutional investors. Comparatively, 32.5% of Aquestive Therapeutics shares are held by institutional investors. 1.5% of Prestige Consumer Healthcare shares are held by company insiders. Comparatively, 6.8% of Aquestive Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Prestige Consumer Healthcare has a beta of 0.33, meaning that its stock price is 67% less volatile than the broader market. Comparatively, Aquestive Therapeutics has a beta of 1.48, meaning that its stock price is 48% more volatile than the broader market.

Prestige Consumer Healthcare has higher revenue and earnings than Aquestive Therapeutics. Aquestive Therapeutics is trading at a lower price-to-earnings ratio than Prestige Consumer Healthcare, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Prestige Consumer Healthcare	$1.10B	1.93	$190.30M	$3.57	12.58
Aquestive Therapeutics	$44.54M	12.99	-$83.78M	-$0.65	N/A

In the previous week, Aquestive Therapeutics had 9 more articles in the media than Prestige Consumer Healthcare. MarketBeat recorded 9 mentions for Aquestive Therapeutics and 0 mentions for Prestige Consumer Healthcare. Prestige Consumer Healthcare's average media sentiment score of 1.00 beat Aquestive Therapeutics' score of 0.55 indicating that Prestige Consumer Healthcare is being referred to more favorably in the media.

Company	Overall Sentiment
Prestige Consumer Healthcare	Positive
Aquestive Therapeutics	Positive

Summary

Prestige Consumer Healthcare beats Aquestive Therapeutics on 9 of the 17 factors compared between the two stocks.

How does Aquestive Therapeutics compare to Bausch Health Cos?

Aquestive Therapeutics (NASDAQ:AQST) and Bausch Health Cos (NYSE:BHC) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, media sentiment, risk, valuation, dividends, profitability and analyst recommendations.

Bausch Health Cos has higher revenue and earnings than Aquestive Therapeutics. Aquestive Therapeutics is trading at a lower price-to-earnings ratio than Bausch Health Cos, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aquestive Therapeutics	$44.54M	12.99	-$83.78M	-$0.65	N/A
Bausch Health Cos	$10.27B	0.21	$157M	-$2.96	N/A

In the previous week, Aquestive Therapeutics had 7 more articles in the media than Bausch Health Cos. MarketBeat recorded 9 mentions for Aquestive Therapeutics and 2 mentions for Bausch Health Cos. Bausch Health Cos' average media sentiment score of 1.14 beat Aquestive Therapeutics' score of 0.55 indicating that Bausch Health Cos is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aquestive Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Bausch Health Cos	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

32.5% of Aquestive Therapeutics shares are owned by institutional investors. Comparatively, 78.7% of Bausch Health Cos shares are owned by institutional investors. 6.8% of Aquestive Therapeutics shares are owned by insiders. Comparatively, 20.7% of Bausch Health Cos shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Bausch Health Cos has a net margin of -10.12% compared to Aquestive Therapeutics' net margin of -144.63%. Aquestive Therapeutics' return on equity of 0.00% beat Bausch Health Cos' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aquestive Therapeutics	-144.63%	N/A	-52.40%
Bausch Health Cos	-10.12%	-561.95%	6.31%

Aquestive Therapeutics presently has a consensus price target of $9.17, indicating a potential upside of 98.84%. Bausch Health Cos has a consensus price target of $8.00, indicating a potential upside of 41.47%. Given Aquestive Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Aquestive Therapeutics is more favorable than Bausch Health Cos.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aquestive Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88
Bausch Health Cos	1 Sell rating(s)	6 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.86

Aquestive Therapeutics has a beta of 1.48, meaning that its stock price is 48% more volatile than the broader market. Comparatively, Bausch Health Cos has a beta of 0.37, meaning that its stock price is 63% less volatile than the broader market.

Summary

Aquestive Therapeutics beats Bausch Health Cos on 9 of the 17 factors compared between the two stocks.

Get Aquestive Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AQST and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AQST vs. The Competition

Export

Metric	Aquestive Therapeutics	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$584.88M	$12.48B	$7.25B	$13.14B
Dividend Yield	N/A	2.63%	2.57%	12.30%
P/E Ratio	-7.09	797.25	275.79	25.40
Price / Sales	12.99	950.97	695.58	114.44
Price / Cash	N/A	88.44	77.42	51.66
Price / Book	-16.46	10.53	10.46	6.33
Net Income	-$83.78M	$2.82B	$3.49B	$358.33M
7 Day Performance	-3.56%	1.69%	0.59%	1.12%
1 Month Performance	0.44%	0.83%	-2.01%	-2.67%
1 Year Performance	-18.69%	3.90%	18.09%	6.01%

Aquestive Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AQST Aquestive Therapeutics	2.568 of 5 stars	$4.61 -1.1%	$9.17 +98.8%	-6.7%	$584.88M	$44.54M	N/A	147	News Coverage Insider Trade
OCUL Ocular Therapeutix	3.1884 of 5 stars	$10.47 -1.4%	$25.75 +145.8%	-21.4%	$2.30B	$52.06M	N/A	230	Analyst Forecast
TRVI Trevi Therapeutics	3.7544 of 5 stars	$15.93 +0.1%	$27.08 +70.1%	+75.1%	$2.27B	N/A	N/A	20	Insider Trade
HCM HUTCHMED	1.726 of 5 stars	$12.85 -2.0%	$14.87 +15.7%	-21.7%	$2.24B	$549.12M	N/A	1,796
PBH Prestige Consumer Healthcare	3.4513 of 5 stars	$47.00 -0.7%	$70.75 +50.5%	-30.0%	$2.23B	$1.09B	13.16	540	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AQST) was last updated on 9/19/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Aquestive Therapeutics (AQST) Competitors

AQST vs. OCUL, TRVI, HCM, PBH, and BHC

How does Aquestive Therapeutics compare to Ocular Therapeutix?

Summary

How does Aquestive Therapeutics compare to Trevi Therapeutics?

Summary

How does Aquestive Therapeutics compare to HUTCHMED?

Summary

How does Aquestive Therapeutics compare to Prestige Consumer Healthcare?

Summary

How does Aquestive Therapeutics compare to Bausch Health Cos?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AQST vs. The Competition

Aquestive Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Aquestive Therapeutics (AQST) Competitors

AQST vs. OCUL, TRVI, HCM, PBH, and BHC

How does Aquestive Therapeutics compare to Ocular Therapeutix?

Does the media prefer OCUL or AQST?

Is OCUL or AQST more profitable?

Which has more risk & volatility, OCUL or AQST?

Do analysts rate OCUL or AQST?

Do insiders and institutionals hold more shares of OCUL or AQST?

Which has stronger valuation and earnings, OCUL or AQST?

Summary

How does Aquestive Therapeutics compare to Trevi Therapeutics?

Does the media prefer TRVI or AQST?

Do institutionals & insiders hold more shares of TRVI or AQST?

Which has more volatility & risk, TRVI or AQST?

Is TRVI or AQST more profitable?

Which has better earnings & valuation, TRVI or AQST?

Do analysts rate TRVI or AQST?

Summary

How does Aquestive Therapeutics compare to HUTCHMED?

Do institutionals and insiders have more ownership in AQST or HCM?

Does the media refer more to AQST or HCM?

Is AQST or HCM more profitable?

Which has better valuation and earnings, AQST or HCM?

Which has more volatility & risk, AQST or HCM?

Do analysts recommend AQST or HCM?

Summary

How does Aquestive Therapeutics compare to Prestige Consumer Healthcare?

Is PBH or AQST more profitable?

Do analysts prefer PBH or AQST?

Do institutionals & insiders have more ownership in PBH or AQST?

Which has more risk and volatility, PBH or AQST?

Which has higher earnings & valuation, PBH or AQST?

Does the media refer more to PBH or AQST?

Summary

How does Aquestive Therapeutics compare to Bausch Health Cos?

Which has better valuation and earnings, AQST or BHC?

Does the media favor AQST or BHC?

Do institutionals & insiders believe in AQST or BHC?

Is AQST or BHC more profitable?

Do analysts recommend AQST or BHC?

Which has more volatility and risk, AQST or BHC?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AQST vs. The Competition

Aquestive Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools